| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2024―Jun―15 |
Biomarkers as Prognosis of COVID-19 Disease: Retrospective Cohort Study |
|
| 2 |
[GO] |
2024―Jun―15 |
Mental Health Disorders After Mild COVID-19: INCREASE IN Fatigue and Depression - A Substudy of the Single-Center Controlled Follow-Up Study of COVID-19 in The District of Constance (FSC19-KN) |
|
| 3 |
[GO] |
2022―Nov―22 |
The Bright Side of COVID-19 Pandemic Vis-À-Vis Neglected Diseases: Three Asylum Seeker -Patients with TB- COVID19 Co-Infections |
|
| 4 |
[GO] |
2022―Nov―22 |
Safety and Efficacy of Nebulised Anti-Inflammatory Solution of Alkaline Hypertonic Ibuprofen (AHI) for Treatment of SARS-Cov-2 Infection: A Compassionate Study with a Comparator Arms |
|
| 5 |
[GO] |
2022―Nov―21 |
Management of Covid-19 based on Risk Features |
|
| 6 |
[GO] |
2022―Nov―21 |
Prospective, Non-Controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients with Mild to Moderate Pneumonia |
|
| 7 |
[GO] |
2022―Nov―21 |
Clinical Features, Pathobiology, Efficacy, and Toxicity of Tenofovir Disoproxil Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections |
|
| 8 |
[GO] |
2021―Dez―18 |
Inspiratory Muscle Training with an Electronic Device to Facilitate Weaning Ventilatory of a Patient with COVID-19 |
|
| 9 |
[GO] |
2021―Dez―18 |
Inhalation of Sodium Pyruvate to Reduce the Symptoms and Severity of Respiratory Diseases Including COVID-19, Long COVID, and Pulmonary Fibrosis |
|
| 10 |
[GO] |
2021―Dez―18 |
Tocilizumab’s Efficacy in Severe COVID-19 Patients: Fact or Fiction |
|
| 11 |
[GO] |
2021―Dez―18 |
Larkin: FDA Emergency Use Authorized Treatment Protocol of DeltaRex-G for Severe Covid-19 [IND# 27185] |
|
| 12 |
[GO] |
2021―Jan―31 |
Lung Cancer and COVID-19: Therapeutic Implications |
|
